Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.

Also called NCT02498769

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 1/2
Enrolled
  • 130 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02498769
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02498769. Randomized; quadruple masking; primary purpose prevention. Start 2015-09 (actual); primary completion 2017-09-28 (actual). Results posted on 2018-12-07.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery
Intervention (Drug)
Botulinum Toxin Type A
Intervention (Drug)
Placebo
Lead sponsor
Joseph Mathew, M.D. (class: other)
Collaborator
Foundation for Anesthesia Education and Research (class: other)
Collaborator
American Heart Association (class: other)

Record details

Record id
cardio:ct-nct02498769
Content hash
ea6675703b60a152a499e6518fd6018f0f7d8ac34b5df4696c1f0c7d0781f14a